{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:03:23Z","timestamp":1756425803811,"version":"3.44.0"},"reference-count":15,"publisher":"BMJ","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2020,10,8]]},"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>An 82-year-old man with an extensive medical history presented to the emergency room with complaints of generalised weakness and cough. He tested positive for COVID-19 10 days prior to presenting to the emergency room. Although his symptoms started a week prior to diagnosis, his weakness increased, warranting emergency response. A comprehensive metabolic panel was drawn from the patient on admission, indicating markedly high liver function tests (LFTs) \u226520 times above the upper limit of normal. On day 1 of admission, the decision was still made to start remdesivir (5-day course) due to decompensated acute respiratory failure as well as dexamethasone. The patient\u2019s LFTs significantly improved throughout his hospital stay. The patient made a full recovery and was discharged on day 10 of hospitalisation.<\/jats:p>","DOI":"10.1136\/bcr-2020-239210","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T16:40:20Z","timestamp":1604162420000},"page":"e239210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infection"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2450-4428","authenticated-orcid":false,"given":"Andrew J","family":"Sabers","sequence":"first","affiliation":[{"name":"Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2423-8761","authenticated-orcid":false,"given":"Amber L","family":"Williams","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4218-7718","authenticated-orcid":false,"given":"T Michael","family":"Farley","sequence":"additional","affiliation":[{"name":"Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, Iowa, USA"},{"name":"Pharmacy, Mercy Hospital Iowa City, Iowa City, Iowa, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"2025082801204630000_13.10.e239210.1","unstructured":"World Health Organization . Pneumonia of unknown cause \u2013 China. Available: https:\/\/www.who.int\/csr\/don\/05-january-2020-pneumonia-of-unkown-cause-china\/en\/ [Accessed 27 Aug 2020]."},{"key":"2025082801204630000_13.10.e239210.2","unstructured":"World Health organization disease (Covid-19) Dashboard. Available: http:\/\/covid19.who.int [Accessed 27 Aug 2020]."},{"key":"2025082801204630000_13.10.e239210.3","doi-asserted-by":"crossref","unstructured":"Beigel JH , Tomashek KM , Dodd LE , et al . Remdesivir for the treatment of Covid-19 \u2014 final report. N Engl J Med Overseas Ed 2020.doi:10.1056\/NEJMoa2007764","DOI":"10.1056\/NEJMoa2007764"},{"key":"2025082801204630000_13.10.e239210.4","article-title":"Infectious diseases Society of America guidelines on the treatment and management of patients with COVID-19","author":"Bhimraj","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025082801204630000_13.10.e239210.5","unstructured":"COVID-19 Treatment Guidelines Panel . Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of health. Available: https:\/\/www.covid19treatmentguidelines.nih.gov\/ [Accessed 25 Aug 2020]."},{"key":"2025082801204630000_13.10.e239210.6","doi-asserted-by":"crossref","DOI":"10.1002\/hep.31480","article-title":"Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis","author":"Bertolini","year":"2020","journal-title":"Hepatology"},{"key":"2025082801204630000_13.10.e239210.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2025082801204630000_13.10.e239210.8","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(20)30057-1"},{"key":"2025082801204630000_13.10.e239210.9","doi-asserted-by":"crossref","unstructured":"Goldman JD , Lye DCB , Hui DS , et al . Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med 2020.doi:10.1056\/NEJMoa2015301","DOI":"10.1056\/NEJMoa2015301"},{"key":"2025082801204630000_13.10.e239210.10","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"2025082801204630000_13.10.e239210.11","unstructured":"Fact sheet for health care providers emergency use Authorization (EUA) for use of Veklury\u00ae (remdesivir), 2020. Available: http:\/\/www.fda.gov\/media\/137566"},{"key":"2025082801204630000_13.10.e239210.12","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of Remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N Engl J Med"},{"key":"2025082801204630000_13.10.e239210.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032"},{"key":"2025082801204630000_13.10.e239210.14","article-title":"Drug-Induced liver injury in a COVID-19 patient: potential interaction of remdesivir with P-glycoprotein inhibitors","author":"Leegwater","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025082801204630000_13.10.e239210.15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40264-020-00954-z","article-title":"Drug-Induced liver injury and COVID-19 infection: the rules remain the same","volume":"43","author":"Olry","year":"2020","journal-title":"Drug Saf"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2020-239210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:20:56Z","timestamp":1756369256000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2020-239210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":15,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10,31]]},"published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1136\/bcr-2020-239210"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2020-239210","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}